Tracked deals
3
3 tracked deals across 2020-2025.
London, England, United Kingdom
London-based investment firm focused on partnering with and relaunching European companies facing temporary financial challenges. Specialises in middle-market equity and debt special situations.
Tracked deals
3
3 tracked deals across 2020-2025.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
1 buyout · 1 divestiture · 1 growth capital
Last 3 years
Supporting Data
Strategic Value Partners-managed funds and Blantyre-managed funds have acquired OQ Chemicals, which will reinstate its historic name OXEA. OXEA is a global manufacturer of oxo intermediates and performance chemicals with primary production sites in Germany and Texas and more than 1,200 employees worldwide; the buyers said they plan to support growth, product portfolio expansion and operational resilience.
L1 Health and Blantyre Capital have acquired European pharmaceutical businesses Remedica (Cyprus) and Sun Wave Pharma (Romania) as part of a debt-for-assets restructuring with Johannesburg-listed Ascendis Health; the deal closed on October 21. Remedica is a generics manufacturer with production and distribution across 160 countries, while Sun Wave Pharma is a leading nutraceuticals/nutritional-products provider in Eastern Europe.
London-based special situations investor Blantyre Capital has made a multi‑million pound growth investment in The McAvoy Group, a leading offsite modular building manufacturer serving the UK and Ireland. The McAvoy family remain shareholders and active in the business; funds will support the group's expansion programme and digital construction strategy, with a Blantyre director joining the board.
Turn tracked acquisition activity into an outreach-ready buyer list.